A clinical study on alopecia areata


  • Kishan Ninama Department of Dermatology, Smt B K Shah Medical Institute and Research Centre Dhiraj Hospital, Sumandeep Vidyapeeth, Piparia, Gujarat
  • Rashmi Mahajan Department of Dermatology, Smt B K Shah Medical Institute and Research Centre Dhiraj Hospital, Sumandeep Vidyapeeth, Piparia, Gujarat
  • F. E. Bilimoria Department of Dermatology, Smt B K Shah Medical Institute and Research Centre Dhiraj Hospital, Sumandeep Vidyapeeth, Piparia, Gujarat
  • Ashvin Vaghani Consultant, Botad, Gujarat




Alopecia areata, PRP, Treatment modalities


Background: Alopecia areata (AA) is a common auto-immune condition, causing hair loss. This disease has limited treatment modalities. Through this study, comparison between established modalities of treatment such as oral mini pulse therapy, intralesional corticosteroids and platelet-rich plasma (PRP) as a newer modality has been done. The objective of the study was to evaluate the efficacy and safety of various treatment modalities in alopecia areata.

Methods: 45 patients with alopecia areata presenting to the OPD of Dermatology, Dhiraj hospital, Pipariya were included in this study. It was conducted as a randomized prospective study for a period of 16 weeks. After taking informed consent, patients were randomly distributed into three treatment groups. Group 1 patients were treated with Tab. Betamethasone 0.1 mg/kg every Saturday and Sunday, Group 2 was treated with Inj. Triamcinolone acetonide 10 mg/ml for scalp and 2.5 mg/ml for eye brows and face was injected into deep dermis; Group 3 was treated with Dermaroller followed by application of activated platelet rich plasma (PRP). SALT score was calculated at first visit and 16 weeks. Regrowth was calculated using Mac Donald and Null Horis grading Scale at 16 weeks.

Results: The SALT score reduced from 13.27 to 7.52 in Group 1, 13.93 to 8.16 in Group 2 and 42.32 to 21.12 in Group 3. Mean grade of regrowth of hairs observed was 3.47, 3.80, 2.93 in Group 1, 2, 3 respectively. The results were analysed using paired t test.

Conclusions:Intralesional corticosteroids viz. triamcinolone acetonide still remains the first choice of therapy for AA in adults with limited involvement. Systemic corticosteroids give lower response than intralesional steroids. Platelet Rich Plasma (PRP) showed promising results, especially in children and in extensive involvement. Compared to other treatment modalities Inj. PRP is safe and with less side effects.



Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol. 1998;38(3):418-25.

Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-8.

AlKhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part II. Treatment. J Am Acad Dermatol 2010;62:191-202.

Ito T. Advances in the management of alopecia areata. J Dermatol. 2012;39:11-7.

Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse methylprednisolone therapy for severe alopecia areata: An open prospective study of 45 patients. J Am Acad Dermatol. 1998;39:597-602.

Kar BR, Handa S, Dogra S, Kumar B. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol. 2005;52:287-90.

Thappa DM, Vijaikumar S. Intravenous dexamethasone pulse therapy for extensive alopecia areata. Indian J Dermatol. 1999;44:187-90.

Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol. 1996;35:133-6.

Pasricha JS, Kumrah L. Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. Indian J Dermatol Venereol Leprol. 1996;62:106-9.

Khaitan BK, Mittal R, Verma KK. Extensive alopecia areata treated with betamethasone oral mini-pulse therapy: An open uncontrolled study. Indian J Dermatol Venereol Leprol. 2004;70:350-3.

Tang L, Cao L, Sundberg J, et al. Restoration of hair growth in mice with an alopecia areata like disease using topical anthralin. Exper Dermatol. 2004;13:1-5.

Rokhsar CK, Shupack JL, Vafai JJ, et al. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol. 1998;39(5, pt1):751-61.

Wiseman MC, Shapiro J, MacDonald N, Lui H. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol. 2001;137:1063-8.

Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol. 1985;12:644-9.

Yoon T, Kim Y. Infant alopecia universalis: role of topical PUVA (psoralen ultraviolet A) radiation. Int J Dermatol. 2005;44:1065-7.

Weiss VC, West DP, Fu TS, Robinson LA, Cook B, Cohen RL, et al. Alopecia Areata Treated with Topical Minoxidil. Arch Dermatol. 1984;120:457-63.

Ferrando J, Grimalt R. Partial response of severe alopecia areata to cyclosporine A. Dermatology. 1999;199:67-9.

Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-2.

Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol. 2004;51:S149-50.

Coronel-Perez IM, Rodriguez-Rey EM, Camacho-Martinez FM. Latanoprost in the treatment of eyelash alopecia in alopecia areata universalis. J Eur Acad Dermatol Venereol. 2010;24:481-5.

Gundogan C, Greve B, Raulin C. Treatment of alopecia areata with the 308-nm xenon chloride excimer laser: case report of two successful treatments with the excimer laser. Lasers Surg Med. 2004;34:86-90.

Zakaria W, Ostovari N, Lacour JP, Ortonne JP. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol. 2004;51:837-8.

Yoo KH, Kim MN, Kim BJ, Kim CW. Treatment of alopecia areata with fractional photothermolysis laser. Int J Dermatol. 2010;49:485-7.

Marx RE, Garg AK. Dental and Craniofacial Applications of Platelet-Rich Plasma. Chicago: Quintessence Publishing; 2005.

Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines. Part II. National Alopecia Areata Foundatin. J Am Acad Dermatol. 2004;51:440-7.

American Association of Blood Banks technical manual committee. Method 6.11: Preparation of platelets from whole blood. In: Vengelen-Tyler V, editor. AABB Technical Manual, 13 th ed. Bethesda (MD): American Association of Blood Banks; 1999: 725.

Contellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive Alopecia Areata. J Am Acad Dermatol. 2001;44:73–6.

Mac Donald H. Guidelines for the management of Alopecia Areata. British Journal of Dermatology. 2003;149:692-9.

Porter D, Burton JL. A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in Alopecia Areata. Br J Dermatol. 1971;85:272–3.

Abell E, Munro DD. ntralesional treatment of Alopecia Areata with triamcinolone acetonide by jet injector. Br J Dermatol. 1973;88:55–9.

Trink A, Sorbellini E, Bezzola P, Rodella L, Rezzani R, Ramot Y, Rinaldi F. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol. 2013;169:690–4.

Singh S. Role of platelet-rich plasma in chronic alopecia areata: Our centre experience. Indian J Plast Surg. 2015;48:57-9.






Original Research Articles